Effective Osteogenic Priming of Mesenchymal Stem Cells through LNA-ASOs-Mediated <i>Sfrp1</i> Gene Silencing

• Main Authors: Daniel García-Sánchez, Alberto González-González, Patricia García-García, Ricardo Reyes, María Isabel Pérez-Núñez, José A. Riancho, Carmen Évora, José Carlos Rodríguez-Rey, Flor M. Pérez-Campo
• Format: Article
• Language: English
• Published: MDPI AG 2021-08-01
• Series: Pharmaceutics
• Subjects: mesenchymal stem cells; bone regeneration; LNA-ASO; GapmeR; <i>Sfrp1</i>; osteogenesis
• Online Access: https://www.mdpi.com/1999-4923/13/8/1277

Mesenchymal stem cell (MSC) transplantation has emerged as a promising approach for bone regeneration. Importantly, the beneficial effects of MSCs can be improved by modulating the expression levels of specific genes to stimulate MSC osteogenic differentiation. We have previously shown that <i>Smurf1</i> silencing by using Locked Nucleic Acid-Antisense Oligonucleotides, in combination with a scaffold that sustainably releases low doses of BMP-2, was able to increase the osteogenic potential of MSCs in the presence of BMP-2 doses significantly smaller than those currently used in the clinic. This would potentially allow an important reduction in this protein in MSs-based treatments, and thus of the side effects linked to its administration. We have further improved this system by specifically targeting the Wnt pathway modulator <i>Sfrp1</i>. This approach not only increases MSC bone regeneration efficiency, but is also able to induce osteogenic differentiation in osteoporotic human MSCs, bypassing the need for BMP-2 induction, underscoring the regenerative potential of this system. Achieving successful osteogenesis with the sole use of LNA-ASOs, without the need of administering pro-osteogenic factors such as BMP-2, would not only reduce the cost of treatments, but would also open the possibility of targeting these LNA-ASOs specifically to MSCs in the bone marrow, allowing us to treat systemic bone loss such as that associated with osteoporosis.